5.87
2.98%
+0.17
Angiodynamic Inc stock is currently priced at $5.87, with a 24-hour trading volume of 428.80K.
It has seen a +2.98% increased in the last 24 hours and a +2.44% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $5.62 pivot point. If it approaches the $5.88 resistance level, significant changes may occur.
Angiodynamic Inc Stock (ANGO) Financials Data
Angiodynamic Inc (ANGO) Revenue 2023
ANGO reported a revenue (TTM) of $329.54 million for the quarter ending November 30, 2023, a +0.49% rise year-over-year.
Angiodynamic Inc (ANGO) Net Income 2023
ANGO net income (TTM) was -$14.12 million for the quarter ending November 30, 2023, a +56.85% increase year-over-year.
Angiodynamic Inc (ANGO) Cash Flow 2023
ANGO recorded a free cash flow (TTM) of -$6.92 million for the quarter ending November 30, 2023, a +68.15% increase year-over-year.
Angiodynamic Inc (ANGO) Earnings per Share 2023
ANGO earnings per share (TTM) was -$0.35 for the quarter ending November 30, 2023, a +57.83% growth year-over-year.
Angiodynamic Inc Stock (ANGO) Latest News
Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for
Zacks Investment Research
AngioDynamics (ANGO) Declines More Than Market: Some Information for Investors
Zacks Investment Research
Why AngioDynamics (ANGO) Dipped More Than Broader Market Today
Zacks Investment Research
AngioDynamics (ANGO) Gains But Lags Market: What You Should Know
Zacks Investment Research
Here's Why AngioDynamics (ANGO) Gained But Lagged the Market Today
Zacks Investment Research
AngioDynamics (ANGO) Divests Its PICC & Midline Businesses
Zacks Investment Research
About Angiodynamic Inc
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support. It also offers thrombolytic catheters to deliver thrombolytic agents; angiographic products and accessories for use in during peripheral vascular interventional procedures; drainage products, which drain abscesses and other fluid pockets; and micro access sets. In addition, the company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; and Asclera injection for treating uncomplicated spider and reticular veins of the lower extremities. Further, it provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation system; and radiofrequency ablation products for ablating solid cancerous or benign tumors. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Cap:
|
Volume (24h):